Fulcrum Therapeutics, Inc.
US ˙ NasdaqGM ˙ US3596161097

SecurityFULC / Fulcrum Therapeutics, Inc.
InstitutionEngineers Gate Manager LP
Latest Disclosed Ownership126,109 shares
Latest Disclosed Value $ 967,256
Engineers Gate Manager LP ownership in FULC / Fulcrum Therapeutics, Inc.

On May 15, 2026 - Engineers Gate Manager LP filed a 13F-HR form disclosing ownership of 126,109 shares of Fulcrum Therapeutics, Inc. (US:FULC) valued at $967,256 USD as of March 31, 2026. The entity filed a previous 13F-HR on August 14, 2025 disclosing 0 shares of Fulcrum Therapeutics, Inc.. The current value of the position is $424,987 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F FULCRUM THERAPEUTICS COM 359616109 126,109 126,109 967 0.0121
2025-08-14 2025-06-30 13F FULCRUM THERAPEUTICS COM 359616109 0 -12,519 -100.00 0 -100.00
2025-05-15 2025-03-31 13F FULCRUM THERAPEUTICS COM 359616109 12,519 12,519 36 0.0006
2025-02-14 2024-12-31 13F FULCRUM THERAPEUTICS COM 359616109 0 -25,234 -100.00 0 -100.00
2024-11-14 2024-09-30 13F FULCRUM THERAPEUTICS COM 359616109 25,234 5,374 27.06 90 -26.83 0.0018
2024-08-14 2024-06-30 13F FULCRUM THERAPEUTICS COM 359616109 19,860 19,860 123 0.0028
2023-08-14 2023-06-30 13F FULCRUM THERAPEUTICS COM 359616109 0 -29,822 -100.00 0 -100.00
2023-05-15 2023-03-31 13F FULCRUM THERAPEUTICS COM 359616109 29,822 29,822 85 0.0036
2022-11-14 2022-09-30 13F FULCRUM THERAPEUTICS COM 359616109 0 -21,356 -100.00 0 -100.00
2022-08-15 2022-06-30 13F FULCRUM THERAPEUTICS COM 359616109 21,356 21,356 105 0.0038
2021-11-15 2021-09-30 13F FULCRUM THERAPEUTICS COM 359616109 0 -11,773 -100.00 0 -100.00
2021-08-16 2021-06-30 13F FULCRUM THERAPEUTICS COM 359616109 11,773 -5,371 -31.33 123 -39.11 0.0079
2021-05-17 2021-03-31 13F FULCRUM THERAPEUTICS COM 359616109 17,144 -2,667 -13.46 202 -12.93 0.0100
2021-02-16 2020-12-31 13F FULCRUM THERAPEUTICS COM 359616109 19,811 -294 -1.46 232 45.91 0.0101
2020-11-16 2020-09-30 13F FULCRUM THERAPEUTICS COM 359616109 20,105 20,105 159 0.0075
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.